Par Drugs And Chemicals Limited has informed the Exchange about Copy of Newspaper Publication
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Par Drugs and Chemicals Limited has submitted copies of newspaper advertisements (The Economic Times and Navgujarat Samay) publishing its standalone unaudited financial results for the quarter ended June 30, 2025. Total income from operations rose to ₹2,604.64 lakhs, up from ₹2,260.56 lakhs in the same quarter last year (about 15% YoY growth) and from ₹2,232.99 lakhs in the previous quarter. Net profit after tax jumped to ₹332.81 lakhs versus ₹253.31 lakhs YoY (around 31% growth) and ₹165.10 lakhs in the prior quarter. EPS for the quarter stood at ₹2.70, compared to ₹2.06 a year ago and ₹1.34 in Q4 FY25. The company is engaged in API manufacturing as a single business segment and has no subsidiaries, so only standalone results apply.
Strong double-digit YoY growth in both revenue and profit, along with a sharp sequential jump in earnings, signals improving operational performance for shareholders. This could support positive sentiment on the stock, though the company's small scale and standalone-only status mean investors should watch for sustained trends in upcoming quarters.